ResultsIQ

ResultsIQ › Latest results › Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited Q1 FY27 results deck summary

NSE: GAUDIUMIVF · BSE: 544709

Results deck of 14 Aug 2026, summarised by AI from the filing.

Gaudium IVF Q1 FY27 consolidated revenue ₹1937.66 cr, up 9.13%, but EBITDA fell 52.96% to ₹242.40 cr on expansion costs.

Key takeaways

  1. Revenue Consolidated revenue from operations ₹1937.66 cr (Q1 FY26: ₹1775.59 cr, +9.13%).
  2. EBITDA Consolidated EBITDA (ex. other income) ₹242.40 cr (Q1 FY26: ₹515.28 cr, -52.96%).
  3. PAT Consolidated PAT (continuing operations) ₹177.59 cr (Q1 FY26: ₹307.62 cr, -42.27%).
  4. Margins Consolidated EBITDA margin 12.51% (Q1 FY26: 29.02%); PAT margin 9.17% (Q1 FY26: 17.33%).
  5. One-time cost Major expense being one-time marketing cost of ₹253.24 lakhs of SID and ERICA.

Original filing on BSE

Gaudium IVF and Women Health Limited Q1 FY27 results

As filed: Revenue ₹19.4 cr, EBITDA ₹2.4 cr, PAT ₹1.8 cr, EBITDA margin 12.5%.

Not scored. Too small to score: quarter revenue ₹19.4 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹30.4 cr, EBITDA ₹12.2 cr, PAT ₹8.4 cr, EBITDA margin 40.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.4 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −7.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹24.5 cr, EBITDA ₹6.6 cr, PAT ₹3.6 cr, EBITDA margin 26.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹24.5 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.2% in 30 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gaudium IVF and Women Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.